Long‐term treatment with empagliflozin as add‐on to oral antidiabetes therapy in J apanese patients with type 2 diabetes mellitus
Authors:
- 16 March 2015
- journal article
- research article
- Published by Wiley in Diabetes, Obesity and Metabolism
- Vol. 17 (7) , 665-674
Abstract
Aims: To evaluate the safety and efficacy of empagliflozin for 52 weeks as add‐on to one other oral antidiabetes therapy in J apanese patients with type 2 diabetes mellitus ( T2DM ). Methods: Patients on biguanide (n = 133), thiazolidinedione (n = 273), α‐glucosidase inhibitor (n = 139), dipeptidyl‐peptidase‐4 inhibitor (n = 139) or glinide (n = 140) were randomized 1 : 1 to receive empagliflozin 10 or 25 mg double‐blind as add‐on therapy for 52 weeks. Patients on sulphonylurea ( SU ; n = 336) were randomized 2 : 2 : 1 to receive empagliflozin 10 or 25 mg double‐blind or open‐label metformin as add‐on therapy for 52 weeks. The primary objective was to evaluate safety. Change from baseline in glycated haemoglobin ( HbA1c ) at week 52 was a secondary endpoint. Results: Adverse events ( AEs ) were reported in 67.6–84.6% of patients receiving empagliflozin. Confirmed hypoglycaemic AEs (plasma glucose ≤70 mg/dl and/or requiring assistance) were reported in 4.4 and 6.6%, respectively, of patients receiving empagliflozin 10 and 25 mg as add‐on to SU and in 0.0 to 2.9%, respectively, of patients receiving empagliflozin 10 and 25 mg as add‐on to other therapies. Baseline mean ± standard deviation HbA1c ranged from 7.51 ± 0.73 to 8.06 ± 0.76% across background therapy groups. At week 52, adjusted mean ± standard error changes from baseline in HbA1c ranged from −0.77 ± 0.06 to −1.00 ± 0.06% in patients receiving empagliflozin. Conclusions: In J apanese patients with T2DM , empagliflozin 10 and 25 mg as add‐on to one other oral antidiabetes therapy for 52 weeks were well tolerated and were associated with clinically meaningful reductions in HbA1c .Keywords
Funding Information
- Boehringer Ingelheim
- Eli Lilly and Company
- Mitsubishi Tanabe
- Sanofi
- Astellas
- Dainippon Sumitomo
- Pfizer
- MSD
- Kowa Pharmaceutical
- Takeda
- Daiichi Sankyo
- Kyowa Kirin
- Novartis
This publication has 17 references indexed in Scilit:
- Efficacy and Safety of Empagliflozin Monotherapy for 52 Weeks in Japanese Patients with Type 2 Diabetes: A Randomized, Double-Blind, Parallel-Group StudyAdvances in Therapy, 2015
- Global estimates of diabetes prevalence for 2013 and projections for 2035Diabetes Research and Clinical Practice, 2014
- Changes in oral antidiabetic prescriptions and improved glycemic control during the years 2002–2011 in Japan (JDDM32)Journal of Diabetes Investigation, 2013
- Empagliflozin monotherapy with sitagliptin as an active comparator in patients with type 2 diabetes: a randomised, double-blind, placebo-controlled, phase 3 trialThe Lancet Diabetes & Endocrinology, 2013
- Management of Hyperglycemia in Type 2 Diabetes: A Patient-Centered ApproachDiabetes Care, 2012
- The role of the kidneys in glucose homeostasis: a new path towards normalizing glycaemiaDiabetes, Obesity and Metabolism, 2011
- Empagliflozin, a novel selective sodium glucose cotransporter‐2 (SGLT‐2) inhibitor: characterisation and comparison with other SGLT‐2 inhibitorsDiabetes, Obesity and Metabolism, 2011
- Glucose dynamics and mechanistic implications of SGLT2 inhibitors in animals and humansKidney International, 2011
- Diabetes in Japan: a review of disease burden and approaches to treatmentDiabetes/Metabolism Research and Reviews, 2009
- Glycemic Control With Diet, Sulfonylurea, Metformin, or Insulin in Patients With Type 2 Diabetes MellitusProgressive Requirement for Multiple Therapies (UKPDS 49)JAMA, 1999